Aimed Bio Inc.’s ADC Technology Export Shows 60% Response Rate in Phase 1 Clinical Trial… Moving Forward with U.S. Approval Trials
60% Response Rate in Patients with FGFR3 Mutations and Fusion Genes
Phase 3 Clinical Trial for Urinary Tract Carcinoma to Begin in the First Half of Next Year
[Edaily Reporter NA EUN-KYUNG ] #Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans to initiate follow-up clinical trials aimed at securing accelerated approval in the U.S. in the first half of next year.
Biohaven presented the clinical results for BHV-1530 on the 19th (local time) at the joint symposium of the European Organization for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR) held in Barcelona, Spain (ENA 2026).
BHV-1530 is an antibody-drug conjugate (ADC) that targets fibroblast growth factor receptor 3 (FGFR3) on the surface of cancer cells. An ADC is a therapeutic agent that delivers a cytotoxic drug to a tumor by linking it to an antibody that recognizes cancer cells. FGFR3 gene mutations or fusions are abnormalities associated with tumor growth found in some cases of urothelial carcinoma, and targeted therapies are currently being developed to address them.
In this clinical trial, partial responses were observed in 6 out of 10 evaluable patients with confirmed FGFR3-activating mutations or fusions. The objective response rate (ORR) was 60%.
In the urothelial carcinoma patient cohort, 3 out of 5 patients whose disease had progressed following combination therapy with Padsep and Keytruda showed a partial response. This group included patients who had previously received treatment with FGFR inhibitors. A partial response was also observed in one patient with urothelial carcinoma without an FGFR3 mutation.
The combination of Padcept and Keytruda is a primary first-line treatment for advanced urothelial carcinoma. Janssen’s “Valbesa” is an existing FGFR-targeted therapy; the U.S. Food and Drug Administration (FDA) granted accelerated approval for Valbesa in 2019 for urothelial carcinoma with FGFR gene abnormalities.
Responses were also confirmed in head and neck cancer. All three patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma harboring an FGFR3 activation mutation showed partial responses. One patient who received four cycles of treatment experienced an 86% reduction in the size of the target lesion at week 24 of treatment.
In terms of safety, as of the data cutoff date of October 19, no dose-limiting toxicities (DLTs) were reported while escalating the dose up to 12 mg/kg. No treatment-related serious adverse events, deaths, or interstitial lung disease were observed. However, as these are preliminary results from a small-scale clinical trial, safety and duration of response require further validation.
Biohaven held a Type C meeting with the FDA in the fourth quarter of this year. Based on this, the company plans to begin a regulatory clinical trial to support accelerated approval for urothelial carcinoma as early as the first half of 2027. Currently, the company is evaluating both dose escalation in monotherapy and combination therapy with the immunotherapy “Livtayo.”
Park Ji-hyun, Director of the Digital Society Planning Division at the Ministry of Science and ICT, stated during a panel discussion at the “Seminar on Building a Win-Win, Collaborative K-Blockchain E…
curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in pat…
#Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans…